CVM Grand Rounds June 10, 2026
June 10, 2026Information
- ID
- 14275
- To Cite
- DCA Citation Guide
Transcript
- 00:05Everyone,
- 00:06just wanted to welcome everyone
- 00:07to our, weekly grand rounds.
- 00:10Not only the people in
- 00:11the room, but, across the
- 00:12state at our watch parties.
- 00:14Today's a special day, not
- 00:16only because we are celebrating
- 00:18the remarkable achievements and,
- 00:21and career of Doctor. Roosevelt,
- 00:23which we'll hear about a
- 00:24little bit in a moment,
- 00:25but also because we have
- 00:25a wonderful visitor that's here,
- 00:28to to to do so,
- 00:29with Doctor. Chang. So, just
- 00:31a couple of announcements for
- 00:33cardiovascular medicine runaround. It's a
- 00:35CME activity, so please be
- 00:36sure to get your CME.
- 00:39We have this is not
- 00:42we have a few more
- 00:43speakers coming up.
- 00:45Maybe I'm not,
- 00:48I don't know if it's
- 00:50here.
- 00:51So just, remind everyone that
- 00:53next week at this time,
- 00:55next door,
- 00:56we'll be running our faculty
- 00:58translational
- 00:58research
- 01:00seminar,
- 01:01and all are welcome.
- 01:03I don't know who's speaking
- 01:04next week. Do you know
- 01:05Jeff?
- 01:06Okay. We'll we'll you'll learn
- 01:08you'll learn about it just
- 01:09before.
- 01:11And then, the following week,
- 01:13and I encourage, hopefully, everyone
- 01:14to attend,
- 01:15dear friend, former mentee, and
- 01:17the current chair of medicine
- 01:18at Arakan University, Doctor. Zeynep
- 01:20Samad,
- 01:21is coming,
- 01:23fine,
- 01:24to spend a few days
- 01:25with us and,
- 01:26and she is going to
- 01:27share with her share with
- 01:29you her, experience
- 01:31of,
- 01:31leading an institution,
- 01:34with and her global health
- 01:36interests as well as her
- 01:37interest. She is by training,
- 01:41a structural interventional a structural
- 01:43echocardiographer.
- 01:44And so we'll I don't
- 01:45know what she's gonna talk
- 01:46about, but we're excited to
- 01:47have her here visiting with
- 01:48us, in a few weeks.
- 01:49So with that, I'll, ask,
- 01:52Rachel to come up and
- 01:54say a few words about
- 01:55doctor Lowenthal.
- 01:56And the slides are not
- 01:57moving, so I'm not sure
- 01:58exactly why, but
- 02:02now it's moving.
- 02:03Oh, so wait.
- 02:05Do I put up another
- 02:06slide here? No. Wait.
- 02:08Because there's this one. Isn't
- 02:09there that one also? Or
- 02:11Nope. That's it. What about
- 02:12this one? Alright. Well Yeah.
- 02:13This is
- 02:15Alright.
- 02:17I'm so pleased to introduce
- 02:19the Linda Rosenfeld honorary lecturer
- 02:21today, inaugurated in two thousand
- 02:23and twenty two in honor
- 02:24of doctor Rosenfeld's
- 02:25contributions to Yale cardiology and
- 02:27to electrophysiology
- 02:28in general.
- 02:29Doctor Rosenfeld graduated Tufts and
- 02:31then, went to Cornell Medical
- 02:33School where she also did
- 02:34her internship and residency and
- 02:36then came to Yale for
- 02:37a cardiology fellowship in nineteen
- 02:39seventy nine, and she's never
- 02:40left.
- 02:42Doctor Rosenfeld
- 02:43has mentored every Yale EP
- 02:45fellow since that time, both
- 02:47clinically, and I think she's
- 02:48written a paper with every
- 02:49fellow in both adult EP
- 02:51as well as pediatric EP
- 02:53where she has held a
- 02:54joint appointment.
- 02:56Doctor Rosenfeld's dedication to teaching
- 02:59from making the Goodyear service
- 03:00what it is today to
- 03:01the, extensive EKG teaching she
- 03:04does for our, medical students,
- 03:06our fellows, our residents,
- 03:08as well as the,
- 03:10as as well as the,
- 03:12fellows clinic, which she is
- 03:13continuing to mentor in even
- 03:15into her retirement, has led
- 03:16to the naming of our
- 03:17teach of our sectional teaching,
- 03:19award for, her as well.
- 03:22For me personally, one of
- 03:23Linda's, primary contributions
- 03:26as the first female cardiology
- 03:28fellow
- 03:28and faculty member here at
- 03:30Yale has been to change
- 03:32the culture in ways that
- 03:33are pretty dramatic. When Linda
- 03:33started, it was it was
- 03:33just fine to pay the
- 03:34female
- 03:36When Linda started, it was
- 03:37it was just fine to
- 03:38pay the female fellow
- 03:39less, and the seasonal the
- 03:40the, social event of the
- 03:42season was the fellow faculty
- 03:44baseball game. She's changed that
- 03:46culture to one of respect
- 03:47for the contributions of diverse
- 03:49individuals.
- 03:50A bit later, at a
- 03:51time when the university was
- 03:52not doing right by our
- 03:53section, Linda's quiet strength galvanized
- 03:56us to push back. Last
- 03:57night, Linda told me a
- 03:59great story from her fellow
- 04:00days as the, only woman
- 04:02among eight female fellows.
- 04:04Apparently, when Linda started, there
- 04:05were no locker rooms for
- 04:07the cath lab, and so
- 04:08the fellows room served that
- 04:10purpose.
- 04:11After confirming that Linda had
- 04:13a brother,
- 04:14the fellows just went right
- 04:15ahead and changed into their
- 04:17scrubs there in the fellows
- 04:18room. You know, the fellows
- 04:20sounded like a great group,
- 04:22but I'm sure there were
- 04:23many things that were not
- 04:24easy for Linda at that
- 04:25time. And, Linda, thank you
- 04:26for paving the way for
- 04:27the rest of us.
- 04:39I'm sorry. Yeah. Yeah.
- 04:41Next up will be doctor
- 04:42Yibeng Chung introducing our speaker
- 04:44for today.
- 04:50Good afternoon, everyone. Thank you
- 04:52very much for attending our,
- 04:55special, seminars. It's our, great
- 04:57pleasure to welcome doctor Mina
- 04:59Chang as today's,
- 05:01speaker for Lindau Rosenfeld honorary
- 05:03lecture.
- 05:04And so,
- 05:06doctor Chang is a professor
- 05:08of medicine, Cleveland Clinic,
- 05:10Keshe Western University.
- 05:12She received her bachelor degree
- 05:14in, in
- 05:16in
- 05:17science from University of California,
- 05:20San Diego, an MD degree
- 05:22from University
- 05:23of Washington,
- 05:24San Luis. She then pursued
- 05:27the,
- 05:28residency,
- 05:30cardiology fellowship,
- 05:31clinic cardiology, electrophysial fellowship, and
- 05:34a poster fellowship,
- 05:37at WashU.
- 05:38Doctor Chung is internationally recognized
- 05:41leader
- 05:42on atrial fibrillation focusing on
- 05:44post operative
- 05:46AF, applying inflammation mechanism,
- 05:49underlying AF, and investigating
- 05:51AF, genetics and genomics.
- 05:54She has funded a Cleveland
- 05:57Clinic f genomic group with
- 05:59robust
- 06:00f for bi reposophy
- 06:02and a large human atria
- 06:04tissue and a pie and
- 06:05a blood biobank.
- 06:07Very excitingly, doctor Chang has
- 06:09established,
- 06:10the robust patient stem cell
- 06:12program for functional studies of
- 06:14g o s coupled with
- 06:15engineered heart tissue
- 06:17and machine learning and multiarmic
- 06:20approaches.
- 06:21She's a center director
- 06:22for an HRA AI for
- 06:24research center. She also directs
- 06:27the researcher center excellence in
- 06:29cardiovascular
- 06:30translation of functional genomics.
- 06:32Her exciting research has led
- 06:34to impactful publications
- 06:37in journals such as circulation,
- 06:38so research,
- 06:40cell reports, medicine, PNS, data
- 06:42genets, etcetera.
- 06:43Doctor Chang's
- 06:44research has continuously be funded
- 06:47by major
- 06:48agencies such as NIH, including
- 06:50the very
- 06:51outstanding
- 06:53program,
- 06:54program
- 06:55director project,
- 06:57so called p o one,
- 06:58extremely competitive, exciting,
- 07:00entitled f, poster GOS, mechanism
- 07:03to treatment.
- 07:04Doctor Chang has contributed
- 07:06extensively to research a community
- 07:09by serving on NIH study
- 07:10sections.
- 07:11She is the president of
- 07:13Heart Rhythm Society
- 07:15and a chair of the
- 07:16HIS scientific and clinical
- 07:19committee, the ECG,
- 07:21alrysumia committee,
- 07:22the data science,
- 07:24and
- 07:25the COVID rapid
- 07:27response
- 07:28research center.
- 07:30So,
- 07:31doctor Chung has won many
- 07:33awards, including
- 07:35the heart vascular thoracic institute
- 07:37award, HOA clinic,
- 07:40clinic,
- 07:41cardiology council award, HOA
- 07:43brain science to life award.
- 07:46Without further ado, let's welcome
- 07:48doctor Chung
- 07:50to give her lecture titled,
- 07:53the insights from atrial fibrillation,
- 07:56genomics,
- 07:57from
- 07:58bedside to bench and, back
- 08:00again. Thank you, doctor Chung.
- 08:08Thank you so much for
- 08:09that very kind,
- 08:10overstated
- 08:11introduction.
- 08:12Thank you very much. I'm
- 08:13very honored to be here
- 08:15and honored to to
- 08:20be able to honor
- 08:22Linda Rosenfeld.
- 08:29You'll be able to go
- 08:30back.
- 08:31K.
- 08:34Thank you. We've heard a
- 08:36lot about Linda already, and,
- 08:38you know, just she has
- 08:39been such a pioneering
- 08:42person,
- 08:43pioneering
- 08:44in so many aspects, pioneering
- 08:46and setting the stage for
- 08:47all of us women in
- 08:48cardiology and EP. So thank
- 08:50you, Linda, again, for doing
- 08:52that. I mean, I don't
- 08:53think I would be here
- 08:54without all the all the
- 08:56stuff that you took, all
- 08:57the hardships that you took
- 08:58for for all of us.
- 09:01You know, you're known for
- 09:02your patient care and your
- 09:04your
- 09:05managing very complex,
- 09:07controversial patient challenges. You haven't
- 09:09shied away from it.
- 09:10I first got to know
- 09:11Linda a little more because
- 09:21about the basics of basic
- 09:23science behind sarcoidosis.
- 09:25And she assigned me to
- 09:26that section. So it made
- 09:27me, made me look into
- 09:29it very,
- 09:30a little deeper. And actually,
- 09:33from that, I thought, you
- 09:34know what? I wanna start
- 09:35study this. And I wanted
- 09:36to do it in time
- 09:37for this this, this lecture.
- 09:39But I have to say
- 09:40that I haven't completed or
- 09:42done that yet so I
- 09:43can't talk about sarcoidosis.
- 09:44But thank you very much
- 09:46for spurring that.
- 09:47And she's done such work
- 09:49in atrial fibrillation, anticoagulation,
- 09:51left atrial appendage closure. And,
- 09:53you know, those are areas
- 09:54in our field that are
- 09:55that are really important now,
- 09:57even controversial,
- 09:59remote monitoring and, you know,
- 10:00very difficult issues in congenital
- 10:02heart disease. She's also I'm
- 10:04very,
- 10:05very,
- 10:07appreciative of your leadership at
- 10:09Heart Rhythm Society,
- 10:11and you've been, leading the
- 10:12patient caregivers committee. And, again,
- 10:15one of the focuses that
- 10:16I wanted to bring to
- 10:17Heart Rhythm Society was to
- 10:19really strengthen our focus on
- 10:21patients, and you,
- 10:22started all that. You were
- 10:24also on the program committee.
- 10:25So thank you very much
- 10:26for all that you've done,
- 10:27and it's really my great
- 10:28honor to be here, for
- 10:30this lecture.
- 10:32Now what I'm gonna try
- 10:33to do is to talk
- 10:35about what we've learned from
- 10:36AFib genomics and through my
- 10:38career. You know? We've had
- 10:39some highs and some lows
- 10:41and learned from all of
- 10:42that. But, I'm gonna my
- 10:44title the title of my
- 10:45talk is AF Insights from
- 10:47AF Genomics, going from bedside
- 10:50to the bench and then
- 10:51back again and then into
- 10:53the future.
- 10:54So we'll we've learned a
- 10:55lot clinically
- 10:57from our patients with afib.
- 10:58And what can we do
- 11:00to take that,
- 11:01to spur us to,
- 11:03address the gaps for basic
- 11:05translational research? And then how
- 11:07do we take it back?
- 11:08So that's what we're gonna
- 11:09focus about,
- 11:11on today. So this slide
- 11:12shows some of the clinical
- 11:14insights that we can get
- 11:15from our patients with atrial
- 11:16fibrillation. As you know, it's
- 11:18the most common arrhythmia,
- 11:20sustained arrhythmia. There are over
- 11:21fifty million people worldwide,
- 11:23last estimates is that there
- 11:25are about ten million in
- 11:26the US. And if you
- 11:27get to age forty, well,
- 11:28you have a one in
- 11:29four chance of getting atrial
- 11:30fibrillation. It's a very common
- 11:32arrhythmia,
- 11:33and it's associated
- 11:35with stroke
- 11:36and even higher, like, it
- 11:38had a,
- 11:40heart failure and atrial cardiomyopathy.
- 11:42It was always felt to
- 11:43be fairly heterogeneous
- 11:45in terms of its cardiovascular,
- 11:48associations, associated with a lot
- 11:50of different types of cardiovascular
- 11:51stress like obesity,
- 11:53getting older, heart failure, hypertension,
- 11:55diabetes, coronary disease, valve disease.
- 11:58And you could see on
- 12:00these on these two studies
- 12:02here, this very marked age
- 12:04association with AFib.
- 12:08So in the nineteen fifties
- 12:10to nineteen nineties, we understood
- 12:11afib as a reentrant arrhythmia.
- 12:13There was this multiple wavelet
- 12:15hypothesis that was put forth
- 12:17by Gordon Moe and colleagues
- 12:19where
- 12:20afib was due to having
- 12:21multiple
- 12:22reentrant wavelets in
- 12:24the atria, the multiple wavelet
- 12:26hypothesis. So then we knew
- 12:28that structural substrates were very
- 12:29important. The larger the atria,
- 12:31you know, the more likely
- 12:33you were to sustain these
- 12:34reentrant circuits.
- 12:36Then in nineteen ninety eight,
- 12:37there was this very,
- 12:39very important paper and paradigm
- 12:42changing paper that came out
- 12:43of Bordeaux by Michel Hasegara
- 12:46and colleagues. And it wouldn't
- 12:47surprise me if he gets
- 12:49the Nobel Prize for this
- 12:50one of these days. I
- 12:51think a lot of us,
- 12:52several of us are hoping
- 12:53and promoting that. But he
- 12:55published this first paper in
- 12:57New England Journal of Medicine
- 12:58where he showed that there's
- 13:00spontaneous initiation of AFib by
- 13:02these ectopic beats coming from
- 13:03the pulmonary veins. And you
- 13:05can see these little pulmonary
- 13:06vein potentials that start the
- 13:08first few beats of atrial
- 13:10fibrillation.
- 13:11So that really changed how
- 13:12we looked at atrial fibrillation.
- 13:15So we next understood that
- 13:16AFib could start. The first
- 13:18few beats could start from
- 13:19these triggers from the pulmonary
- 13:21veins. And in susceptible people,
- 13:24that they could conduct out
- 13:25to the atrium
- 13:26and cause the reentrant arrhythmia,
- 13:29that we know as atrial
- 13:30fibrillation.
- 13:32And we also had this
- 13:33dual substrate model where what
- 13:36was important were substrates for
- 13:38AF initiation, those triggers from
- 13:39the pulmonary veins, and that
- 13:41you could have substrates for
- 13:42AF maintenance. So hemodynamic,
- 13:44the structural basis for sustaining
- 13:46all these multiple wandering wavelets,
- 13:48and that you could have
- 13:49electrical remodeling and structural remodeling
- 13:51that may, that could occur
- 13:53and make one more important
- 13:55than the other move between
- 13:57this. And there were a
- 13:58lot of, a lot of,
- 13:59triggers that could do this,
- 14:01including stretch, calcium overload, LVH,
- 14:04ventricular dysfunction, valve disease, autonomic
- 14:06tone, inflammation, fibrosis, and toxins.
- 14:09So it seemed to be
- 14:10such a heterogeneous,
- 14:13disease.
- 14:14But we also understood that
- 14:15the natural history of AF
- 14:16from the stool substrate model
- 14:18is that we tend to
- 14:20that people with AFib tend
- 14:21to progress. That early in
- 14:23the in the natural history
- 14:25of the disease, the sources
- 14:26for AF initiation, those triggers
- 14:28may be important. And that
- 14:29may manifest as just having
- 14:31frequent atrial ectopy that then
- 14:33evolves to repetitive runs of
- 14:35atrial tachycardia, paroxysms of AFib
- 14:37that become more and more
- 14:38persistent and even permanent.
- 14:40And later on, the substrates
- 14:42for AF maintenance may be
- 14:44more important.
- 14:46So with these findings, we
- 14:48started doing AF ablation. And
- 14:50the cornerstone of AF ablation
- 14:51was, found to be pulmonary
- 14:53vein isolation.
- 14:54And it turns out this
- 14:55is a figure of the
- 14:57Cox Mays procedure. I trained
- 14:59at, Washington University.
- 15:01And around that time, Jimmy
- 15:02Cox was coming up with
- 15:04this. This was before we
- 15:05knew about the pulmonary vein
- 15:06triggers. He had this operation
- 15:08where his mother He was,
- 15:11I think very stimulated by
- 15:12his mother having atrial fib.
- 15:14So he decided he was
- 15:15going to work on atrial
- 15:15fibrillation. He was a very
- 15:17renowned cardiac arrhythmia surgeon. He
- 15:19would do AVNRT
- 15:20and accessory pathways. And what
- 15:22he did was they had
- 15:23animal models and, and, then
- 15:26brought it to humans where
- 15:27he would make incisions through
- 15:28the atrium and then,
- 15:30resew them up. And you'd
- 15:31have these suture lines. And
- 15:32the thinking was that the
- 15:33reentrant circuits would run into
- 15:34a suture line and you'd
- 15:36extinguish AFib. But we know
- 15:37now that one reason why
- 15:39it was so successful is
- 15:40that there's a box lesion
- 15:41around the pulmonary veins.
- 15:43So this led to a
- 15:45lot of work on catheter
- 15:47ablation.
- 15:48And,
- 15:48we now we've developed radio
- 15:50frequency energy methods and cryoablation
- 15:53to electrically isolate the pulmonary
- 15:56veins. And then more recently
- 15:57over the last couple of
- 15:58years in the US, we've
- 15:59had,
- 16:00pulse field ablation,
- 16:01which has really taken off.
- 16:03And I remember sitting in
- 16:04an auditorium like this at
- 16:06WashU
- 16:07and,
- 16:08and we were Jimmy Cox
- 16:10was doing this live case.
- 16:11And I remember he said,
- 16:12I have to tell you
- 16:14this. This is full of
- 16:15cardiac electrophysiology. He goes, I
- 16:16can tell you this. This
- 16:17is something that those damned
- 16:18electrophysiologists
- 16:19are never gonna do with
- 16:20a catheter. You know? Because,
- 16:22like, you know, he was
- 16:23we were taking away his
- 16:24his business for WPW and
- 16:26AVNRT, but, anyway so look
- 16:28at where we are today.
- 16:31But there are still a
- 16:32lot of gaps in our
- 16:33management of AFib. There's a
- 16:34ceiling of of ablation success.
- 16:36We can't seem to get
- 16:37above eighty to ninety percent
- 16:39success. Even with paroxysmal AFib
- 16:41and even with post fetal
- 16:42ablation, we still see issues
- 16:44with durability.
- 16:45And we see that there's
- 16:46recurrence that occur even after
- 16:48successful PBI. I mean, you
- 16:50you you if you do
- 16:51this procedure, you get, you
- 16:52know, you you you are
- 16:53converted. You are a believer
- 16:54of pulmonary vein isolation that
- 16:56this helps. But then people
- 16:57can recur, you know, several
- 16:59years later. And then we
- 17:00still have pretty poor success
- 17:02rates in persistent AF. And
- 17:03and there's a lot of
- 17:04debate still. Even with post
- 17:06fetal ablation, what should we
- 17:07ablate? Should we be fulgurating
- 17:09the posterior wall? You know?
- 17:10What should we do beyond
- 17:11the pulmonary,
- 17:13vein isolation?
- 17:14And there's still some risks
- 17:15with AFib ablation. Even though
- 17:17it's become a lot safer
- 17:18with post fetal ablation, we're
- 17:19not dealing with atrial esophageal
- 17:21fistula, pulmonary vein stenosis,
- 17:23those kinds of things. We're
- 17:24still dealing
- 17:25with recurrences,
- 17:27new atrial flutters that are
- 17:28developing. And,
- 17:30a late thing that has
- 17:31been turning up is coronary
- 17:33spasm that can happen.
- 17:35And there's a signal for
- 17:36potential late cardiac
- 17:39later, not even first early,
- 17:41within the first few weeks
- 17:42of sudden death. What's that
- 17:43all about? We don't know.
- 17:45Okay?
- 17:46So, you know,
- 17:47there is a role still
- 17:48besides ablation for anturemic drugs
- 17:51but there are a lot
- 17:52of challenges with anturemic drugs.
- 17:53Prorhythmia, intolerance. We haven't had
- 17:56a new anturemic drug in
- 17:57over fifteen years. I looked
- 17:58up Joneterone. It was like
- 17:59over fifteen years ago. And,
- 18:02so, you know, back then
- 18:03we were thinking,
- 18:04are there any upstream therapies
- 18:06that can target this AF
- 18:08substrate?
- 18:09So our group was looking
- 18:11at a lot of the
- 18:11traditional upstream therapies for AFib.
- 18:13We did a study looking
- 18:15at c reactive protein and
- 18:16showed that,
- 18:17that c reactive protein was
- 18:19elevated in afib and, you
- 18:21know, more more and persistent
- 18:22than paroxysmal.
- 18:24We did a study out
- 18:25of the,
- 18:26CHS study because we saw
- 18:28that that they had measured
- 18:29CRP. We were kind of
- 18:30on the tails of coronary
- 18:32disease looking at ultra sensitive
- 18:33CRP. And we saw that
- 18:35they had also coded for
- 18:36AFib. And we showed that
- 18:37CRP could could,
- 18:39could predict future development of
- 18:41AFib. So, I was working
- 18:43with a group of people,
- 18:44including David Van Wagoner, and
- 18:45we were looking at, the
- 18:47influence of upstream
- 18:50factors like inflammation, calcium overload,
- 18:52fibrosis, and oxidative stress and
- 18:54using some of these agents
- 18:55to try to target it.
- 18:56So there are a lot
- 18:57of studies that that came
- 18:59out of that period where
- 19:01we were looking at secondary
- 19:03analyses of randomized trials for
- 19:04these agents. But, unfortunately,
- 19:07with the exception of steroids,
- 19:09which you can't take long
- 19:10term, and statins for post
- 19:12op AF that,
- 19:14and ACE inhibitors and ARBs
- 19:16in heart failure, the randomized
- 19:17trials for AF have been
- 19:19disappointing. You know, it may
- 19:20work in hypertension
- 19:22or in, heart failure but
- 19:23those agents are already, you
- 19:25know, indicated
- 19:26there.
- 19:27So then in the 2000s,
- 19:29we learned that AF can
- 19:31be heritable. There are always
- 19:32some familial cases of AF
- 19:34around. But we also had
- 19:34studies coming out of Framingham
- 19:34that showed that parental AF
- 19:34increases the risk of
- 19:36AF studies coming out of
- 19:36Framingham that showed that parental
- 19:38AF increases the risk of
- 19:40AF in offspring. So they
- 19:42had odds ratios one point
- 19:43eight five. And then if
- 19:44you have earlier onset AF,
- 19:46a parent with AF under
- 19:47seventy five, the odds ratio
- 19:49was three. In Iceland, decode
- 19:51genetics,
- 19:52also showed that, that AF
- 19:54increases the risk of AF
- 19:55in first degree relatives with
- 19:57about, again, a relative risk
- 19:58of one point seven seven.
- 20:00And early onset was,
- 20:02AF was associated with relative
- 20:04risk almost five. Patrick Eleanor
- 20:06at the MGH looked at
- 20:09lone AF and showed that
- 20:10that very greatly increases the
- 20:12risk of AF and family
- 20:13members. And look at these
- 20:14relative risks.
- 20:15Sons, eight. Daughters, nine. Brothers,
- 20:18seventy.
- 20:19Sisters, thirty four. And, if
- 20:21you took a very
- 20:23detailed history, then you could
- 20:24find that thirty percent of
- 20:26people with low AF could
- 20:27have a family history of
- 20:28AF. The Danish Twins Study
- 20:30and the UK Biobank reported
- 20:32AF heritability to be about
- 20:33twenty two percent to sixty
- 20:34two
- 20:35percent. So perhaps
- 20:37genetics could be the upstream,
- 20:39ultimate upstream approach. And around
- 20:41that time, with the sequencing
- 20:42of the human genome, we
- 20:44could assay for markers or
- 20:45single nucleotide polymorphism,
- 20:47SNPs, across the genome,
- 20:50like several hundred thousand of
- 20:51these markers across the genome.
- 20:53And the first for the
- 20:54first time, you can take,
- 20:55you could get information from
- 20:57the patient and do these
- 20:59big, large case control studies
- 21:01where you take a group
- 21:02of people with a condition
- 21:03like afib, a group of
- 21:04people without afib, and look
- 21:06at which areas on the
- 21:07chromosome are associated with your
- 21:09condition.
- 21:10And this is like an
- 21:11unbiased way. Up until this
- 21:12time, we were looking at
- 21:14ion channel drugs, electrical
- 21:16acting drugs, because AF is
- 21:18an electrical disease. And for
- 21:20the first time, we could
- 21:21actually get back from the
- 21:22bedside from our patients what
- 21:24genes might be involved with
- 21:26AFib.
- 21:27So in the 2000s,
- 21:29in two thousand and seven,
- 21:30decode genetics that they had,
- 21:32genotyped a hundred thousand of
- 21:34their population with one of
- 21:35these big, SNP chips. And
- 21:38they reported that there's there
- 21:39was an area on chromosome
- 21:41four that was associated with
- 21:42afib. Understand that within twenty
- 21:44four hours, they, you know,
- 21:45got IRB approval and then
- 21:47crunched that out.
- 21:49Meanwhile, at Cleveland Clinic, you
- 21:51know, we were trying to
- 21:52follow along the genetics as
- 21:53well. And we'd started a
- 21:54lone AF gene bank. And
- 21:56this is our Manhattan plot
- 21:57with about almost five hundred
- 21:59cases for lone AF
- 22:01in two thousand seven.
- 22:03So this Manhattan plot on
- 22:04the x axis is each
- 22:06chromosome, and each dot is
- 22:08a marker, the single nucleotide
- 22:09polymorphism.
- 22:10And on the y axis
- 22:11is negative log of the
- 22:13p value. Because you're looking
- 22:14at hundreds of thousands of
- 22:15SNPs, you have to adjust
- 22:17for multiple testing. So instead
- 22:18of a p value less
- 22:20than point o five, which
- 22:21means five percent of your
- 22:22results are wrong. Right? You
- 22:24you need to adjust for
- 22:25that. So you actually need
- 22:26a p value of less
- 22:27than, like, ten to minus
- 22:28six to ten to minus
- 22:29eight to be of genome
- 22:30wide significance.
- 22:31And you see here that
- 22:33this is this signal is
- 22:34actually really strong on chromosome
- 22:36four. I mean, we we
- 22:37went into this thinking this
- 22:38is a heterogeneous
- 22:40condition. We weren't sure we
- 22:41were going to see any
- 22:42kind of genetic
- 22:43signal in a GWAS.
- 22:45But we could actually see
- 22:46this with a hundred cases.
- 22:48This is like the poster
- 22:49child of GWAS at the
- 22:50time, age related macular degeneration,
- 22:52that they could see a
- 22:53signal with a hundred patients.
- 22:55So we actually never,
- 22:58formally published this paper. We
- 23:00contributed to the,
- 23:02to various consortia.
- 23:03But what's going on at
- 23:05chromosome four? It's in a
- 23:06noncoding region. And it turns
- 23:08out
- 23:09that the gene nearest to
- 23:11it is called Pytx2.
- 23:13Pytx2 is a transcription factor
- 23:15that's active early in development.
- 23:17And it is involved with
- 23:18left right formation of the
- 23:19heart
- 23:20and the pulmonary veins. So
- 23:22we thought, ah, this is
- 23:23gonna be a piece of
- 23:24cake. You know? We just
- 23:25happened to land near a
- 23:26a gene that's involved with
- 23:28formation of the pulmonary veins.
- 23:30So over the years, there
- 23:31were larger and larger genome
- 23:33wide association studies. There was
- 23:35ours,
- 23:36and then we contributed our
- 23:37our data to the CHARGE
- 23:39consortium. It was the NHLBI,
- 23:42cohorts and heart and aging
- 23:43research in genomic epidemiology.
- 23:46And we joined the AFib
- 23:47working group. So with over
- 23:48eighteen thousand cases, about ten
- 23:50years later, there were twenty
- 23:51four AFG WSLOCI. It's actually
- 23:53starting to look like Manhattan.
- 23:54Right?
- 23:55And then in,
- 23:57two thousand eighteen, eighty thousand
- 23:59is looking more crowded.
- 24:00And this is the latest
- 24:01from two thousand twenty five
- 24:03with over a hundred and
- 24:04eighty thousand cases. And we
- 24:06have over three hundred,
- 24:07three hundred and fifty AFGUS
- 24:09loci. But, you know, these
- 24:10are really,
- 24:11small p values. And through
- 24:13it all, the chromosome four
- 24:14q twenty five locus is
- 24:16still the much the very
- 24:17strongest.
- 24:18So as I said, this
- 24:19this gene that's near Pyddix
- 24:21that is near,
- 24:24the the locus is Pyddix
- 24:25two. And it directs left
- 24:27right
- 24:29cardiac,
- 24:30formation, and it's involved with
- 24:31formation of the pulmonary veins.
- 24:33It's expressed in the human
- 24:34and the mouse left atrium
- 24:36and absent in pretty much
- 24:37other areas of the heart.
- 24:39And it suppresses a left
- 24:40atrial sinus node program.
- 24:43So maybe there are triggers
- 24:44here that it is suppressing.
- 24:46And there's a PidX2 deficient
- 24:47mouse model, and they're more
- 24:49susceptible to pacing induced atrial
- 24:50arrhythmias.
- 24:52And these mice don't develop
- 24:53a normal pulmonary vein sleep.
- 24:55There are a lot of
- 24:56complex transcription factor interactions, and
- 24:58it also has a role
- 25:00in early cardiac regeneration
- 25:02and repair.
- 25:03So, you know, could this
- 25:04really explain pulmonary vein triggers?
- 25:06As those of you who
- 25:07do AF ablation, when you
- 25:08ablate and isolate the pulmonary
- 25:10veins, you can see sometimes
- 25:12this isolated firing within the
- 25:14pulmonary veins that's dissociated from
- 25:16what's going on. So this
- 25:18and, and the rest of
- 25:18the atrium, this is a
- 25:19slide showing,
- 25:21a figure showing atrial fibrillation
- 25:22on the atrium. And within
- 25:24the pulmonary veins, you see
- 25:25this firing.
- 25:26And, and this is, independent
- 25:28firing during sinus rhythm. It's
- 25:30hard to make the association.
- 25:31We had a trend toward
- 25:32it. But as you know,
- 25:33you know, especially nowadays, we're
- 25:35probably ablating a lot of
- 25:36those, those triggers. So it's
- 25:37hard to do those associations.
- 25:40But we did do some
- 25:41spatial RNA sequence, seeing from
- 25:43the donor heart tissues to
- 25:45see whether pit x two
- 25:47and, other of these transcription
- 25:49factors are,
- 25:50expressed in the pulmonary veins.
- 25:52These are from donor heart
- 25:53tissues taking the,
- 25:56taking the the junction or
- 25:57the pulmonary veins to left
- 25:59atrium
- 26:00and,
- 26:01did,
- 26:02spatial,
- 26:03RNA sequencing.
- 26:04And, we do see pulmonary,
- 26:07PITUX two expressed in the
- 26:08pulmonary veins and in the
- 26:09left atrial appendage. Some of
- 26:10these are left atrial appendage.
- 26:12And SHOX two, which is
- 26:13another,
- 26:16associated
- 26:17transcription factor. And HCN four,
- 26:19which as many of you
- 26:20may know is the is
- 26:21the pacemaker current. So we
- 26:23do see some sporadic,
- 26:26activity or expression of HTN
- 26:28four in the pulmonary veins
- 26:29in these left atrial,
- 26:30cardiomyocytes.
- 26:36So this is in a
- 26:37weird order. But
- 26:38the question is, can we
- 26:40use some of these gene
- 26:41based,
- 26:43therapies to do, to guide
- 26:44our intervention? Because I said,
- 26:45as I said, I thought,
- 26:47oh, we've hit the jackpot.
- 26:48We could use this PIVX
- 26:49to genotype and tell us
- 26:50who we should do pulmonary
- 26:51vein isolation on. Well, it
- 26:53turns out that, I was
- 26:55wrong. And because these top
- 26:57loci,
- 26:58from GWAS,
- 26:59if anything, are associated with
- 27:01a higher risk of recurrence.
- 27:03So with AF recurrence after
- 27:05cardioversion,
- 27:06on antrimic drugs, and even
- 27:08after,
- 27:08with iblato genetics, some of
- 27:10these risk variants are associated
- 27:11with higher risk for,
- 27:13recurrence. So there's other things
- 27:15going on.
- 27:16And it may be that
- 27:17also there's a role that
- 27:18I mentioned this role of
- 27:19PEDX2 in cardiac regeneration.
- 27:22Jim Martin, who's at Baylor,
- 27:24has a model where he
- 27:25looks at been looking at
- 27:27Piddex two and regeneration.
- 27:29He has a mouse model
- 27:30where the neonatal
- 27:31mice,
- 27:32their hearts, if you lop
- 27:33off their eight their apex,
- 27:35it actually regenerates.
- 27:36But his pit x two,
- 27:38deficient mice don't regenerate. He's
- 27:40also looking that at that
- 27:41in,
- 27:42myocardial infarction and trying to
- 27:45perhaps leverage that. But there's
- 27:47some he's looking at some
- 27:48pretty,
- 27:49complex signaling pathways where it
- 27:51may may work. But it
- 27:53made me ask whether or
- 27:54not this is why we
- 27:56get recurrences. Because we know
- 27:59that,
- 28:00that with atrial fibrillation, we
- 28:01do see kind of a
- 28:03change in the transcriptomic
- 28:04profiling to a more fetal
- 28:06state. Are we reactivating? Are
- 28:07we doing something to to
- 28:09PDX2?
- 28:10So that's not quite worked
- 28:11out yet. But maybe it
- 28:12will tie it together.
- 28:14Okay. So these are some
- 28:15of the things that we've
- 28:16learned from patients on how
- 28:17do we take it to
- 28:17the bench. Because once you
- 28:19found all these things you
- 28:20know, when you have three
- 28:20hundred and fifty loci, there's
- 28:22a lot of work for
- 28:22basic scientists to work on.
- 28:24Right?
- 28:25But it takes a long
- 28:26time to go from that
- 28:28SNP to actually function and
- 28:30actually to treatment.
- 28:31So what our our labs
- 28:32have tried to do is
- 28:33we've tried to follow this
- 28:34this paradigm that genes to
- 28:36function going DNA is transcribed
- 28:38to mRNA,
- 28:39and then we look at
- 28:40mRNA, and then we that's
- 28:41translated to protein, which then
- 28:43leads to function. And we've
- 28:44asked a couple of questions.
- 28:45Like, how is gene expression,
- 28:47affected by AF itself? And
- 28:49can we make some inferences
- 28:51about
- 28:52gene expression and susceptibility
- 28:54and and persistence or progression
- 28:56of AF? And then which
- 28:58are actually the causative
- 29:00risk SNPs and risk
- 29:02genes?
- 29:02Because the SNPs can be
- 29:04in linkage disequilibrium
- 29:05with actually the causal SNPs
- 29:07or the causal genes and
- 29:08it may not actually be
- 29:09next door to it. So
- 29:12we approached that first,
- 29:14asking that second question, you
- 29:15know, what actually are the
- 29:16causative genes?
- 29:18So what we had done
- 29:19over the years in, in
- 29:20conjunction with David Van Wagner,
- 29:22in my group, we have
- 29:23been working very closely with
- 29:25the cardiac surgeons. And, you
- 29:26know, those left atrial appendages
- 29:27that they used to take
- 29:28off? Well, instead of throwing
- 29:30them away, we've been hoarding
- 29:31them to a an atrial
- 29:33tissue bank. And so what
- 29:34that's allowed us to do
- 29:36is to take the, the
- 29:38genetics and see, and, and
- 29:40say, and see, look at
- 29:41which of those snips, those
- 29:43markers are associated with change
- 29:45in expression.
- 29:46So here we have looking
- 29:47at the nearby, you have,
- 29:49an allele that's G here
- 29:50and C and the G
- 29:51allele is associated with higher
- 29:52expression. Whereas,
- 29:53expression, whereas, the c doesn't
- 29:55make as much. So you
- 29:57can make inferences about finding
- 29:59what the causal,
- 30:00SNP is and the causal
- 30:01gene is by doing that.
- 30:02It's called expression quantitative
- 30:05trait loci. We treat mRNA
- 30:06expression as a quantitative trait.
- 30:09So this is another thing
- 30:10we thought, you know, was
- 30:11gonna be a piece of
- 30:12cake. Right? We're gonna find
- 30:13which of these are causative.
- 30:15So in this twenty seventeen
- 30:17Manhattan plot, we had found,
- 30:20EQTLs,
- 30:20associations with about half of
- 30:22them, in blue and light
- 30:24blue and and red. They
- 30:26weren't necessarily next to each
- 30:27other. But, you know, our
- 30:28top candidate here, we couldn't
- 30:30see an association with Piddex
- 30:32too. Darn.
- 30:33It wasn't quite as a
- 30:35home run as we thought
- 30:36it was gonna be. So
- 30:37why is that? I think
- 30:38really it's because timing. We're
- 30:40looking in adults. Okay? And
- 30:43this PidX2 is active early
- 30:44in development. So we're kind
- 30:46of missing that. And then
- 30:47location, location, location. It's not
- 30:49just in real estate. We're
- 30:51looking at left atrial appendage.
- 30:53But, you know, maybe the
- 30:54action really is in the
- 30:55pulmonary vein, left atrial junction.
- 30:57That's a lot harder to
- 30:57get the tissue of. But
- 30:59we did look at it.
- 31:00I showed you some of
- 31:00the spatial. We did see
- 31:02some associations. But it's just
- 31:03not going to reach genome
- 31:04wide significance.
- 31:06So
- 31:08now we also, we were
- 31:09also trying to figure out
- 31:10this age paradox. If we're
- 31:11seeing all these,
- 31:13these signals that are active
- 31:14early in development, how come
- 31:15people don't get it until
- 31:16their fifties, sixties, seventies, and
- 31:18eighties? The age paradox.
- 31:21So to do that, that's
- 31:22where adult left atrial appendages,
- 31:24the tissue may be helpful.
- 31:27And so what we did
- 31:28was the first thing we
- 31:29did was we divided them.
- 31:30We have about a thousand.
- 31:31We heavily studied two hundred
- 31:33and fifty to three hundred
- 31:34of them. And we divide
- 31:35them into people who don't
- 31:37have any history of AFib.
- 31:38So they're in sinus rhythm,
- 31:39and then a group that
- 31:40has a history of AFib,
- 31:42but they're in sinus rhythm
- 31:43at the time that we
- 31:43get the tissue and a
- 31:44peep and a group of
- 31:45people that have,
- 31:47AFib and they're in AFib.
- 31:49And you can make some
- 31:50inferences
- 31:51about AF susceptibility
- 31:53by comparing the controls, no
- 31:54AF to the AF sinus
- 31:55rhythm, and maybe on persistence,
- 31:57going from paroxysmal to, persistent
- 32:00from that. The it's very
- 32:01difficult to interpret though, because
- 32:03just being an AFib changes
- 32:04gene expression a a lot.
- 32:06As you can see with
- 32:07this heat map, this is
- 32:08basically those group comparisons, and
- 32:10these are genes that are
- 32:11different.
- 32:12And it's like looking at
- 32:13alphabet soup, really, to be
- 32:14honest. It makes you your
- 32:15eyes kind of glaze over.
- 32:17It makes my eyes glaze
- 32:18over. So what you tend
- 32:20to do with these is
- 32:21you can do pathway analysis,
- 32:22and you do what's called
- 32:23gene set testing, where you
- 32:24analyze groups of genes because
- 32:26that can be more robust
- 32:27than analyzing single genes alone.
- 32:30So this is another area
- 32:31in my career where I
- 32:32thought, you know, we were
- 32:33we were gonna have it.
- 32:34I'm going, I'm telling my
- 32:35group, you know, this is
- 32:36not gonna be that interesting.
- 32:37We've been studying inflammation, you
- 32:39know, and oxidative stress. We're
- 32:41just gonna see an increase
- 32:42in that. So to my
- 32:43surprise, what we saw was
- 32:45that if susceptibility and persistence,
- 32:47instead of being,
- 32:48associated with an elevated level,
- 32:50was associated with lower levels
- 32:52of some of these stress
- 32:53pathways,
- 32:54a decrease in some of
- 32:55the transcriptional responses to cell
- 32:57stress, including some oxidative stress
- 32:59pathways, protein handling stress,
- 33:01the heat shock, you know,
- 33:03factors,
- 33:04and, that lead to loss
- 33:06of proteostasis.
- 33:07And so that was kind
- 33:10of a new concept for
- 33:11me, at least. So and
- 33:12actually focusing on that heat
- 33:14shock response, a decrease in,
- 33:16in, proteostasis.
- 33:18Heat shock response is this
- 33:20system that's designed to protect
- 33:22our cells from stress. And
- 33:23it ensures that your proteins
- 33:25are folded appropriately. And one
- 33:27of the hallmarks of aging
- 33:28is loss of this proteostasis.
- 33:30And, heat shock factor one,
- 33:32which popped up in our,
- 33:34look on other slide, is
- 33:35the master regulator of this
- 33:37heat shock response in mammals.
- 33:38So what happens is when
- 33:40our cells are exposed to
- 33:42stress, like,
- 33:44heat stress, endoplasmic
- 33:46reticular stress, oxidative stress, the
- 33:48proteins tend to
- 33:50unfold.
- 33:51And cells take care of
- 33:52that by doing things like
- 33:54eating it up, autophagy,
- 33:56and using some of these
- 33:57heat talk factors to,
- 33:59to get lysosomal
- 34:01degradation.
- 34:02And there's proteasomal
- 34:03degradation
- 34:05and then refolding that's chaperone
- 34:06mediated by some of these
- 34:07heat shock factors. But when
- 34:09this pathway is overwhelmed,
- 34:11then these unfolded proteins,
- 34:13they precipitate
- 34:15in aggregates.
- 34:16And those aggregates, they they
- 34:18they,
- 34:19actually precipitate as amyloid.
- 34:22Okay? And so they're insoluble
- 34:24protein aggregates from misfolded protein
- 34:26components.
- 34:27And,
- 34:29it turns out that there's
- 34:30some studies out there that
- 34:31shows that atrial amyloid is
- 34:32actually quite common. And there's
- 34:34one paper. And if you're
- 34:35over age eighty
- 34:36ninety, the ninety percent of
- 34:38those atrial had it had
- 34:39atrial amyloid. And some studies
- 34:41have associated, they've done some
- 34:43co labeling and shown that,
- 34:46ANP, atri natriuretic peptide, is
- 34:48associated with some of those
- 34:49aggregates.
- 34:50And, you know, you, you're
- 34:51familiar with ANP. You've probably
- 34:53talked to some of your
- 34:54patients who have AFib. They
- 34:55go into AFib and they
- 34:56start peeing a lot. The
- 34:57diuretic
- 34:58approach. We know that from
- 34:59our atrial,
- 35:00appendages, this AMP is really
- 35:03highly expressed. And so, you
- 35:05know, this may be one
- 35:06causative area.
- 35:08So this is a study
- 35:09that we did looking at
- 35:10left atrial amyloid that we're
- 35:12but we haven't published yet.
- 35:13But it's a small pilot
- 35:14study that we're trying to
- 35:16expand where we did Congo
- 35:17red staining
- 35:18in twenty eight left atrial
- 35:19appendage,
- 35:20samples
- 35:21matched for with, with or
- 35:23without AFib, matched for sex
- 35:24age and BMI. And you
- 35:25see that there's an increase
- 35:27in, left atrial amyloid
- 35:29associated with AFib, and it
- 35:30was not associated with age,
- 35:32sex, hypertension, or BMI.
- 35:34We also took our,
- 35:36expression, our our RNA,
- 35:38seek analysis and did gene
- 35:40coexpression to see if we
- 35:41can find other genes that
- 35:43are associated with not just,
- 35:44you know, when not just
- 35:45the GWAS hits. And we
- 35:46did pathway analysis. And what
- 35:48we found were a lot
- 35:50of metabolic pathways that were
- 35:52implicated,
- 35:53with oxidative phosphorylation,
- 35:55mitochondrial dysfunction,
- 35:56and also the stress response
- 35:58pathways.
- 35:59So we devised this dual
- 36:00risk model, like the perfect
- 36:02storm for AF, a two
- 36:03hit hypothesis for AFib, as
- 36:05you may hear for cancer,
- 36:08where you may be born
- 36:09with genetic susceptibility to AFib
- 36:11that can lead to these
- 36:12pulmonary vein triggers,
- 36:14early in life. But it
- 36:15takes a second hit,
- 36:17with stressors later in life
- 36:19before if actually manifests. So
- 36:21So for example, the stresses
- 36:22of aging, and I tell
- 36:23you that is very stressful,
- 36:25and obesity especially and, can,
- 36:28can cause a lot of
- 36:29metabolic protein and mitochondrial stress.
- 36:32And that may be what
- 36:34actually leads to AFib. So
- 36:35in genetically susceptible patients,
- 36:37inadequate transcriptional
- 36:39responses to stress may predispose
- 36:41to AF later in life.
- 36:43So this gives us a
- 36:44potential for a lot of
- 36:45novel upstream
- 36:46therapies. And, also, it gives
- 36:48you hope that perhaps you
- 36:49can actually target some of
- 36:51these things with lifestyle risk
- 36:51factor modification and,
- 36:54defer or avoid AFib.
- 36:56But what things that we
- 36:58and others have identified is
- 36:59that there are potential,
- 37:01large numbers of novel upstream
- 37:03targets, candidate pathways
- 37:05with metabolic stress pathways, mitochondrial
- 37:07dysfunction, proteostasis,
- 37:09and a whole host of
- 37:10candidate genes,
- 37:12some of whom which are
- 37:13listed here.
- 37:15So how do we take
- 37:16this back to the bedside?
- 37:17Okay. So can we use
- 37:19the GWAS data
- 37:21to help us predict AFib?
- 37:23Well, this is kind of
- 37:24a complicated
- 37:25slide. But it turns out
- 37:26that each individual SNP in
- 37:28a GWAS has very small
- 37:29effect sizes, but you can
- 37:30combine them to generate these
- 37:32polygenic risk scores. So this
- 37:34is a study from Steve
- 37:35Lubez's group and, that looked
- 37:38at the predictive accuracy
- 37:39of clinical versus genetic risk
- 37:41models for AFib.
- 37:43And they looked at age
- 37:44just being older older than
- 37:45age sixty five. There's a
- 37:47CHARGE AF score, which is
- 37:48a clinical risk score. And
- 37:50then they have this eleven
- 37:51hundred and sixty eight variant
- 37:52polygenic risk score and then
- 37:54a PREDICT AF score that
- 37:55combined the clinical and the
- 37:57polygenic risk. And they had
- 37:59five hundred thousand individuals from
- 38:00several cohorts. And I think
- 38:02what, one of the things
- 38:03we learned is that age
- 38:05is actually a pretty good
- 38:06predictor of AF. The AUC,
- 38:08see statistics here are, like,
- 38:09point six seven five to
- 38:11point eight. It's hard to
- 38:12beat those, actually. And then
- 38:13if you add the clinical
- 38:14risk factors, charge AF, it
- 38:16adds,
- 38:17a little bit better performance
- 38:18over age, you know, point
- 38:20summons, point eight again.
- 38:22And and if you actually
- 38:23do the polygenic risk score
- 38:25alone, it's actually not that
- 38:26impressive. Right? Point five six,
- 38:28point six.
- 38:29If you add it all
- 38:30together, you do get some
- 38:31incremental,
- 38:34improvement in predictive
- 38:35accuracy. But really, the genetic
- 38:38polygenic risk score, you get
- 38:39it's marginally
- 38:40of value. It's quite modest,
- 38:42although it is greatest among
- 38:44younger individuals.
- 38:46There is a new policy,
- 38:47some new polygenic risk scores
- 38:49that includes some that includes
- 38:50that mega GWAS. So here's
- 38:52one with one point one
- 38:54million variants to see if
- 38:55we can do better.
- 38:57And it's combined, it's comparing
- 38:59to, the CHARGE AF clinical
- 39:00risk score. And again, you
- 39:02see
- 39:03c statistics putting them all
- 39:04together about point eight, point
- 39:06eight
- 39:07seven.
- 39:08So and then when you
- 39:09add the,
- 39:10the the polygenic risk score
- 39:12in these, it adds, you
- 39:13know, just very small,
- 39:15modest effect.
- 39:16So it's kinda hard to
- 39:18say you can use this,
- 39:20to try to predict AF.
- 39:23But I think one thing
- 39:24that we've learned from all
- 39:25these genetic studies is that
- 39:27there's a lot of overlap
- 39:28of AF with structural heart
- 39:29disease. Of course, you could
- 39:30you know, we knew that
- 39:31already.
- 39:32But what's really interesting is
- 39:33if you start looking at
- 39:34other GWASs like for heart
- 39:36failure,
- 39:37there's a lot of commonality
- 39:38between some of the hits.
- 39:39So you see this area
- 39:41on chromosome four near FedEx
- 39:43two. This happens to be
- 39:44a very high hit, a
- 39:45top top hit in this
- 39:46GWAS of heart failure.
- 39:48And if you look at
- 39:49some of the genes where
- 39:51you look at rare coding
- 39:52variants that have been implicated
- 39:53in early onset AI,
- 39:55then and you you look
- 39:56at,
- 39:58genes that have high confidence
- 40:00for cardiomyopathy
- 40:01or arrhythmia syndromes in yellow
- 40:03and, these,
- 40:05genes that,
- 40:07are actionable in the middle.
- 40:09There's a lot of overlap
- 40:10here. And if you see
- 40:11this, if you could see
- 40:12this, a lot of these
- 40:13are structural genes that you
- 40:15know from the cardiomyopathy
- 40:17realm. Okay?
- 40:19So this is a more
- 40:21recent study that looked at
- 40:22sequencing over fifty thousand cases
- 40:25of AF looking for rare
- 40:27variants.
- 40:28Right? As I said, GOS
- 40:29identifies the common variants that
- 40:30have very small effect sizes.
- 40:32But a parallel approach could
- 40:34be looking for doing the
- 40:35whole genome sequencing we can
- 40:36do now in exome sequencing
- 40:38to identify rarer variants that
- 40:40actually have large effects.
- 40:42So this,
- 40:43this paper from Patrick Eleanor
- 40:45group, Eleanor's group looked at
- 40:47sequencing over fifty thousand. And
- 40:49over half of their population
- 40:51with AF were diagnosed before
- 40:53age sixty five. And the
- 40:54strongest association
- 40:55was for,
- 40:57TTN, which codes for site
- 40:59Titan, a very large protein
- 41:01with variants that are associated
- 41:02with cardiomyopathy.
- 41:04And there are other cardiomyopathy
- 41:05genes identified too, like myosin
- 41:07binding protein C3, which is
- 41:08a hypertrophic cardiomyopathy
- 41:10gene, lamin A, you know,
- 41:11implicated in cardiomyopathy
- 41:13and conduction defects, placophilin
- 41:15two, which is an ARVD
- 41:17gene, and some other genes
- 41:19also associated with arrhythmias. And
- 41:20there also overlap with GWAS
- 41:22genes.
- 41:23So if you look at
- 41:24sets of these rare variants,
- 41:25they're associated with, you know,
- 41:27muscle cell, adipose tissue, cardiac
- 41:29physiology,
- 41:30and pathology,
- 41:31associations,
- 41:33as well as, you know,
- 41:34actin, real cytoskeletal,
- 41:36cardiomyopathy
- 41:38type,
- 41:43recommendation that we added to
- 41:44the AF guidelines a couple
- 41:46of years back, where there's
- 41:47a recommendation
- 41:48from AF guidelines that it's
- 41:49reasonable to do genetic testing
- 41:51in patients with early onset
- 41:53AFib.
- 41:54And, and these prior studies
- 41:55from TOPMed and the smaller
- 41:57studies have shown that seventeen
- 41:59to twenty four percent of
- 42:00these may have rare variants
- 42:01in cardiomyopathy
- 42:02or channelopathy
- 42:03genes. A lot of these
- 42:04genes that we've already touched
- 42:06upon.
- 42:07And here's some newer data.
- 42:09People will say, well, what
- 42:10are you going to do
- 42:10with it? You know, we're
- 42:11going to probably have to
- 42:12do more,
- 42:14more surveillance in these people.
- 42:16So this, is a paper
- 42:17that comes from Ben Shoemaker's
- 42:19group at Vanderbilt. And they
- 42:21looked at two thousand eight
- 42:22hundred patients that had AF.
- 42:24And they had genetic testing
- 42:25done for cardiomyopathy
- 42:27and arrhythmia genes. And what
- 42:28they found was that,
- 42:30two percent had a pathogenic
- 42:32or likely pathogenic
- 42:33variant in the titin gene.
- 42:36And they looked at they
- 42:37compared, you know, Titan versus
- 42:38not,
- 42:40people that didn't have these,
- 42:42variants. And they found that
- 42:43the Titan patients more often
- 42:45had low QRS voltage.
- 42:47So perhaps when you see
- 42:48this AF patient and and
- 42:50they have low voltage considered
- 42:51genetic testing, and they seem
- 42:53to have a worse course
- 42:54with more often having persistent
- 42:57AF, more often having cardioversions.
- 43:00And, at the end of
- 43:01their follow-up, which was about
- 43:04eight years, I think, I
- 43:05wrote there, then eleven percent
- 43:08versus four percent had sustained
- 43:09VT or VF. And by
- 43:11then, eighteen percent had ICDs,
- 43:13forty four percent had developed
- 43:15LV systolic dysfunction,
- 43:17and forty seven percent had
- 43:18a combined endpoint of ventricular,
- 43:21heart failure, reduced ER, or
- 43:22sustained VTVR.
- 43:24So this this genetic testing
- 43:26couldn't make a difference.
- 43:29And then,
- 43:33so bringing this a little
- 43:34more for,
- 43:35forward even more, this is
- 43:37another study that this group
- 43:38did on impact of management
- 43:40of doing the genetic testing
- 43:41in early onset AF. So
- 43:43they looked at two hundred
- 43:44forty six patients that had
- 43:45early onset AFib. They did
- 43:47genetic testing.
- 43:48And they found,
- 43:50a pathogenic or lightly pathogenic
- 43:52variant in twenty percent. And
- 43:54they could document a change
- 43:55in management happened in about
- 43:57half of them. And so
- 43:59this, included starting GDMT,
- 44:01you know, stroke prevention, getting
- 44:03a new ICD,
- 44:04or directing lifestyle intervention.
- 44:07So, in summary, our polygenic
- 44:09risk scores, with clinical variables
- 44:11can identify increased risk rate
- 44:13in the general population that
- 44:14might then be targeted for
- 44:16increased surveillance, possibly with more
- 44:18wearable device monitors. But they
- 44:20can also potentially identify patients
- 44:22at risk for AF maybe
- 44:23after certain more, targeted groups
- 44:26like cryptogenic
- 44:27stroke or something like that
- 44:28that could trigger preventive therapies
- 44:30like anticoagulation
- 44:31for people at high risk.
- 44:33But the genetic testing for
- 44:34early onset AF is really
- 44:36here today and can help,
- 44:38you identify variants in these
- 44:39cardiomyopathy
- 44:40genes and perhaps personalize their
- 44:42arrhythmia management. So, hopefully, in
- 44:44the future, we'll be able
- 44:45to use this data to
- 44:46even identify more novel tar
- 44:48targets and therapies for individualized
- 44:50management.
- 44:52So where do we go
- 44:53from here?
- 44:54We were fortunate to get
- 44:55a program project grant to
- 44:56try to take forward some
- 44:58of this information after a
- 44:59genome wide association study to
- 45:01look at mechanisms to therapeutics
- 45:03trying to identify some of
- 45:04the remaining gaps. So we
- 45:06have four projects going on.
- 45:07One is to work on
- 45:08some of the individual,
- 45:10GWAS hits and trying to
- 45:12get them from genes to
- 45:13function and hopefully new,
- 45:15drugs. We are looking at
- 45:17genes and metabolism and looking
- 45:18at the role of obesity
- 45:19in some of these mouse
- 45:20models of AI and, metabolic
- 45:23stress.
- 45:24Genes and nutrition. We have,
- 45:26one looking
- 45:27a project looking in the
- 45:28microbiome that looks really interesting.
- 45:30And then, we have this
- 45:32genes to omics informed drugs.
- 45:34So I'm gonna spend the
- 45:34last few,
- 45:36minutes talking about, this, genes
- 45:38to drugs. So it turns
- 45:40out that genetically
- 45:41supported targets,
- 45:42can double the clinical development
- 45:44success rate. So we're working
- 45:46with Peisheng Chen who,
- 45:48uses a network systems biology
- 45:50approach to trying to repurpose
- 45:51drugs and for drug discovery.
- 45:54And what this does is
- 45:55it takes a lot of
- 45:56the publicly
- 45:57available information, protein protein interactums,
- 46:00and tries to layer a
- 46:01bunch of other information
- 46:03on that. So this,
- 46:05this approach, we're using genomic
- 46:07data for AF target,
- 46:10drug target identification. So we're
- 46:12taking a protein protein interactome,
- 46:14layering it with the data
- 46:15that we get from our
- 46:17tissues with transcriptomics,
- 46:18our RNA seek, mega GWAS
- 46:21data, the gen genetic data,
- 46:22coexpression data, the expression,
- 46:25and sequence, and protein,
- 46:27quantitative trait loci, a lot
- 46:28of the stuff you can
- 46:29get from from omics, proteomics.
- 46:31And then we're layering on
- 46:32single nuclei RNA seek to
- 46:34try to get more, cardiomyocyte
- 46:36or other,
- 46:37other cell based,
- 46:39specific disease modules. So we
- 46:41can create an AF disease
- 46:42module. And then there are
- 46:43these databases out there that
- 46:45are drug target databases. And
- 46:47we can use those drug
- 46:48target databases to do network
- 46:50based proximity analysis, trying to
- 46:51find the closest distance. Like,
- 46:53trying to find drugs that
- 46:54act on your genes or
- 46:56the proteins of interest. You
- 46:58come up with this candidate
- 46:59drug list.
- 47:01So
- 47:02and then what you can
- 47:02do is, you know, it's
- 47:03like bringing Coles to Newcastle
- 47:05here. You can test these
- 47:06drugs in these, cardiomyocyte
- 47:08models that are derived from
- 47:10inducible pluripotent stem cells with
- 47:12or without atrial fibrillation.
- 47:14And these are pretty amazing.
- 47:15I don't know if you,
- 47:17see these. When I first
- 47:18saw this, I was, like,
- 47:19blown away. It looks like
- 47:20a map. Right? You know,
- 47:21there must be some nodal
- 47:22cells in there, and you
- 47:23can see the act
- 47:25activity rippling through the monolayers.
- 47:27In fact, they're doing it
- 47:28too much because they're ripping
- 47:29off the
- 47:30the media is coming coming
- 47:32off, so it makes it
- 47:33really hard to,
- 47:35to actually measure. But, you
- 47:36know, it's pretty amazing to
- 47:38see some of these in
- 47:39culture, and you can grow
- 47:40them in engineered heart tissue.
- 47:42And here, you know, you
- 47:43have Yibei and other people
- 47:44who are really looking at
- 47:46this in a much more
- 47:47sophisticated way. But this is
- 47:49one,
- 47:50one model where you can
- 47:51grow these within on these
- 47:52flexible posts and it exercises
- 47:54them. So that helps them
- 47:56mature. One of the issues
- 47:57with, just growing them in
- 47:58a monolayer that they tend
- 48:00to be kind of immature.
- 48:01But you can, you know,
- 48:02test them, and then you
- 48:03can do transcriptomic
- 48:05profiling to show,
- 48:07that these are more mature,
- 48:09more like, left atrial appendage,
- 48:13profiles. You can use these
- 48:14engineered heart tissues to look
- 48:16at, the effect of metabolic
- 48:17stressors. So here you have
- 48:19one,
- 48:20in engineered heart tissue, and
- 48:21then you give isoproterenol, as
- 48:23you know, it'll make it
- 48:24beat faster. You can do,
- 48:25contractility
- 48:26profiling. You can do optical
- 48:28mapping.
- 48:29So we're using this, this
- 48:31pathway to try to identify
- 48:33and functionally test drugs, to
- 48:35target AF progression. So we're
- 48:37doing that network based, approach
- 48:39and then testing,
- 48:41trying to test candidate drugs
- 48:43in these engineered heart tissues.
- 48:44And then we'll go to
- 48:45some mouse models.
- 48:47I think one of our
- 48:48issues has been trying to
- 48:49find a phenotype for AFib
- 48:51in a in vitro. They
- 48:53don't fibrillate. You know, your
- 48:55car your so that's been
- 48:56difficult. So we're using transcriptomic
- 48:59profiling at that point. So
- 49:00this is our first paper
- 49:02where we, published it. We
- 49:03were focusing on repurposing FDA
- 49:05approved drugs because that can
- 49:06reduce the cost of drug
- 49:08development. These drugs are already
- 49:09well studied. So you can
- 49:10go you can infer,
- 49:12you know, safety
- 49:13and effectiveness. So,
- 49:15this was, the pipeline I
- 49:17showed you. This is our
- 49:18first AF disease network, and
- 49:20it highlights, two hundred and
- 49:21forty five of these were,
- 49:24they were,
- 49:25were AF enriched genes. And
- 49:26this is our first,
- 49:28drug target, the top fifty
- 49:30five drug candidates that were
- 49:32nominated by the network proximity
- 49:34analysis. One of the drugs
- 49:35in here is metformin.
- 49:37And that really caught our
- 49:38eye as well because we
- 49:39were interested in metformin from
- 49:41one of the, functional,
- 49:43studies on one of the
- 49:44hits on FAM thirteen b,
- 49:46chromosome five. And it turns
- 49:47out that if he taught
- 49:48factor one is a master
- 49:50regulator of protein stress responses,
- 49:52AMP kinase is a master
- 49:53regulator of metabolic stress. And
- 49:55AMP kinase looks at AMP,
- 49:58ATP ratios.
- 49:59So it's activated and and
- 50:01responds,
- 50:02to increased AMP, ATP ratios,
- 50:05and it can increase ATP
- 50:06generation and decrease ATP
- 50:08expenditures. So this is really,
- 50:10interesting to us.
- 50:12And, it turns out that
- 50:13metformin, a very common prediabetes
- 50:15and diabetes drug, caloric restriction,
- 50:18like dieting, weight loss, and
- 50:20exercise,
- 50:21have some potential beneficial effects
- 50:23on AMP kinase. And as
- 50:25many of you know, there's
- 50:26our colleagues from, Australia
- 50:28have done a lot of
- 50:29studies looking at lifestyle risk
- 50:30factor modification, weight loss, and
- 50:32exercise, and showing a decrease
- 50:33in AFib.
- 50:35So,
- 50:36this is the rationale for
- 50:37trying to look at metformin.
- 50:39As I've said, you know,
- 50:40the activity
- 50:41on AMP kinase, there's also
- 50:42like a diabetes,
- 50:44study that seemed to have
- 50:46lower AFib in people on
- 50:47in metformin.
- 50:49We took it to those
- 50:50iPS cells
- 50:51and tried to look at
- 50:52gene expression, and it had
- 50:53some,
- 50:55we stressed them with pacing
- 50:57and saw that there were
- 50:58some,
- 50:59favorable effects on heat shock
- 51:00factor,
- 51:02expression, protein expression, and also
- 51:03on some ion channel, calcium,
- 51:05channel, and and SCN five
- 51:07a. So we designed this,
- 51:09study called TRIMAF targeting risk
- 51:11intervention in metformin for AFib.
- 51:13And it was a two
- 51:14by two study,
- 51:16with forearms control metformin lifestyle
- 51:19risk factor modification and lifestyle
- 51:21plus metformin.
- 51:22And, this was done in
- 51:23patients that had implanted atrial
- 51:25devices, pacemakers with defibrillators, so
- 51:28we could get daily AF
- 51:29burden and a lot of
- 51:30activity.
- 51:31So I'm sad to say
- 51:33that the first year was
- 51:34not easy because what happened
- 51:36was
- 51:38we hadn't realized this, but
- 51:39our standard of care group,
- 51:40we had blasted them with
- 51:42all of our preventive
- 51:44cardiology written materials. And we'd
- 51:46done a lot of modeling
- 51:47including in that. And if
- 51:48burden goes up with time,
- 51:49as soon as they entered
- 51:51our study,
- 51:52if burden started going down,
- 51:53it was hard to to
- 51:54beat that. And the other
- 51:56issue was that metformin had
- 51:57a lot of side effects.
- 52:00So this was before GLP-1RAs
- 52:01and that kind of thing.
- 52:02That was the only thing
- 52:02we had. Half of the
- 52:03people had to stop metformin.
- 52:05So that was difficult, actually.
- 52:06And I just wonder whether
- 52:07or not we saw poorer
- 52:09effects because they had all
- 52:10these GI side effects. We
- 52:11probably, they probably had a
- 52:13higher inflammatory load and all
- 52:14that. So we're still waiting
- 52:16on the second year follow-up
- 52:17and maybe some of that
- 52:18standard of care effect will
- 52:19wear off. But, you know,
- 52:20it made us sit back
- 52:21and think, well, can we
- 52:23we what we had done
- 52:24with it was we had,
- 52:26saved, all their blood and,
- 52:29their peripheral blood mononuclear cells
- 52:31that we can then reprogram
- 52:32to iPS cells. And what
- 52:34we could do is is
- 52:36correlate people who have
- 52:38a response to metformin or
- 52:40stress and and and people
- 52:41who didn't respond and now
- 52:43probably test it in vitro.
- 52:45So that's what we're working
- 52:46on now. And, hopefully, it'll
- 52:48it could be, like, one
- 52:49of the first,
- 52:50to, studies to try to
- 52:52correlate, you know, response in
- 52:54a clinical trial, response to
- 52:55a drug versus in vitro.
- 52:57So
- 52:58our next steps are to
- 52:59try to refine,
- 53:01the disease network, adding our
- 53:03single nuclear RNA seq, etcetera,
- 53:05and improving our prioritization
- 53:07workflow. A lot of our
- 53:08our targeting is done using
- 53:10cancer cell lines for drugs.
- 53:12And we see on the
- 53:13list, some toxic drugs. So
- 53:15to try to narrow it
- 53:16down, we need to, do
- 53:17a lot better. So we're
- 53:18now doing trying to create
- 53:20a resource where we're looking
- 53:21at drug targeting onto our,
- 53:23cardiomyocytes.
- 53:25So hopefully, we'll have better
- 53:27news in the future.
- 53:28But, I I think it's
- 53:30still a very promising approach
- 53:32and, look forward to hopefully
- 53:34updating you in the future.
- 53:35So in summary, our large
- 53:36GWAS for AFib implicate over
- 53:38a hundred, now, you know,
- 53:39three hundred AF.
- 53:41The top locus is near
- 53:42gene implicated in pulmonary vein
- 53:44formation. And our transcriptomic study
- 53:46suggests that AF is associated
- 53:47with impaired or overwhelmed responses
- 53:49to cell stress. And going
- 53:51to the bedside, the stool,
- 53:52the, the bench or dual
- 53:54risk model proposals that in
- 53:55genetically susceptible individuals, inadequate transcriptional
- 53:58responses to stress predisposes to
- 54:00AF in later life. And
- 54:02then going from bedside, going
- 54:03back to that side that
- 54:04maybe we'll find these dreams
- 54:06that these drugs that can
- 54:07target some of these pathways
- 54:08that,
- 54:09we can now, study for
- 54:10AI. And, hopefully, the integration
- 54:12of all this information will
- 54:14become easier and easier maybe
- 54:15in this era of AI
- 54:16to help us identify new
- 54:18drugs. So thank you very
- 54:19much again for inviting me.
- 54:20Thank you, Linda, for being
- 54:21such an, inspiration.
- 54:23And I wanna thank our
- 54:24team. It takes really a
- 54:26village to work on all
- 54:27of this.
- 54:28And you see a lot
- 54:29of other names here. Thank
- 54:31you.
- 54:34Yeah.
- 54:37Mina, that was fantastic and
- 54:39just tremendous amount of work.
- 54:41Maybe, I'd have to put
- 54:42Linda on the spot, but
- 54:43do you have a chance
- 54:44do you would you like
- 54:45to ask the first question?
- 54:47No? Okay. I always ask.
- 54:50So, maybe I'll start and
- 54:51then, I'm sure there'll be
- 54:52others.
- 54:53You know, you've kind of
- 54:54projected the opportunity to kind
- 54:56of pursue
- 54:57what I'm gonna call facilitated
- 54:59ablation, maybe, conceptualize it,
- 55:03of identifying individuals
- 55:05who might be pursuing,
- 55:07ablate curative ablation strategies,
- 55:10who might have high polygenic
- 55:12risk scores, and then maybe,
- 55:14possibly pursuing,
- 55:17therapeutic strategies in the pathways
- 55:19where they have those that
- 55:21high risk.
- 55:22Is that a a construct
- 55:24that you're pursuing in in
- 55:25your,
- 55:26in your program project grant?
- 55:28And and what do you
- 55:29think about that idea and
- 55:30that future?
- 55:31Well, I mean, that's a
- 55:32great question because that that
- 55:34when we looked at those
- 55:35top GWAS hits and peep
- 55:37other people have done a
- 55:38lot of these studies,
- 55:39they're either no signal Ben
- 55:41did a a kind of
- 55:42an ablation
- 55:44success,
- 55:45GWAS.
- 55:46And,
- 55:47there's a signal that they're
- 55:48actually associated with higher risk
- 55:50of recurrence. So I don't
- 55:51think we can use it
- 55:52to actually select at this
- 55:53point. But the question is,
- 55:55what is that locus doing?
- 55:57And, why is it that
- 55:59people are getting it? So
- 56:00the way we're trying to
- 56:01approach it is we have
- 56:02another grant that's been looking
- 56:03at imaging.
- 56:04So we have done a
- 56:05lot of CTs and MRIs.
- 56:07We're collaborating with Ben Shoemaker
- 56:09at, Vanderbilt
- 56:10and, Rod Passman,
- 56:12with the MRI at Northwestern
- 56:14and Anat Madhubushi, who used
- 56:16to be at Case, now
- 56:17at Emory,
- 56:18doing a lot of radiomic,
- 56:20machine learning,
- 56:22analyses of the images to
- 56:24see what's different
- 56:26genetically
- 56:27about the pulmonary veins. So
- 56:28it's taken us a long
- 56:29time because they try to,
- 56:33associate with a pulmonary vein
- 56:35morphology has been really challenging.
- 56:36But that's something that we're
- 56:37looking at. And are there
- 56:39areas
- 56:40of of the atria that
- 56:41we should be targeting more?
- 56:42And I have learned from
- 56:43it. I mean, there's some
- 56:44areas that we've seen that
- 56:46are associated with recurrence, you
- 56:47know, like inferior to the
- 56:49right things like that that
- 56:51that already changing my
- 56:53my my practice without, you
- 56:55know, without,
- 56:57you know, major publication. But
- 56:59I think that's an area
- 56:59that we really wanna
- 57:01hit.
- 57:05Mina,
- 57:06wonderful talk. I'm it it's
- 57:08amazing that you propose this
- 57:10to hit a a mechanism
- 57:12for f. So I'm wondering
- 57:14besides the pulmonary vein trigger,
- 57:17you mentioned in f,
- 57:18patient, they have reduced
- 57:20stress response pathway.
- 57:23What is the potential
- 57:24reasoning for those f patient?
- 57:26They have reduced stress response.
- 57:29Yeah. It's kind of hard
- 57:30to say. I mean, is
- 57:31it AF itself that is
- 57:33overwhelming,
- 57:34that we're that that these
- 57:36things are overwhelming? So the
- 57:37the the reason why it's
- 57:39decreased is not that
- 57:41not that known. And, you
- 57:42know, I think we were
- 57:43talking yesterday, today, where in
- 57:45paroxysmal may some of these
- 57:46pathways are increased, but once
- 57:48you get to persistent,
- 57:49they're decreased. So what's going
- 57:50on there? Are we overwhelming
- 57:52overwhelming it? You know? And
- 57:54I think that's really a
- 57:55a question to be answered.
- 57:57And there's there's a lot
- 57:58more complexity there that we
- 57:59have not even begun to
- 58:00touch because on that one
- 58:02slide, there's actually,
- 58:04a signal for increased
- 58:06myocyte differentiation.
- 58:07So what's going on there?
- 58:08You know, are we
- 58:09going to cardiofibroblast,
- 58:11fibocardium, or whatever those things
- 58:12are? Are we so so
- 58:14there's a lot more there
- 58:16to unpack, but it's a
- 58:17great question in which I
- 58:18knew the answer to that.
- 58:22Thank you so much for
- 58:22an amazing talk and amazing
- 58:24research.
- 58:25My question is about the
- 58:26GWASes taking covariates
- 58:28for the environmental
- 58:30risk factors
- 58:32and, what your thoughts are
- 58:33about that if those if
- 58:34the studies did take things
- 58:36like obesity, BMI,
- 58:38alcohol consumption as as covariates,
- 58:40and whether we should be
- 58:41doing that or whether we
- 58:42should actually be looking at
- 58:43gene environment interaction to kinda
- 58:46maximize that signal rather.
- 58:48There used to be more
- 58:49done with that. We haven't
- 58:51really
- 58:51you know, because that would
- 58:52be really important for us
- 58:54to see what how how
- 58:56modifiable
- 58:57this really is. And so
- 58:58that's been a challenge incorporating
- 59:00all that. And and a
- 59:01lot of these have been
- 59:02done in big population studies.
- 59:04So I think and and
- 59:05some, that kind of data
- 59:07are are,
- 59:09are, you know, collected. So
- 59:10I think within charge, they
- 59:12probably have that.
- 59:14I don't know that we
- 59:14actually incorporated that in any
- 59:16of these big g mega
- 59:17GWASes, but maybe that's the
- 59:19next step. It's a great
- 59:20idea.
- 59:22A a great talk. One
- 59:23of the benefit of genetic
- 59:25testing is that actually,
- 59:27you can do segregation
- 59:28analysis and do cascade screening.
- 59:31But the problem I see
- 59:32here is that inheritance from
- 59:34the father to child is
- 59:35much lower than sibling.
- 59:37One reason being actually that
- 59:38your SNPs are actually randomly
- 59:41distributed in among your children.
- 59:43So we cannot use that
- 59:44for
- 59:45cascade screening and, you know,
- 59:48understanding who is at risk
- 59:49at from the children of
- 59:50AFib. We know if a
- 59:52person has AFib has AFib
- 59:53already. But the children, we
- 59:55cannot do that. Now you
- 59:56have also rare variants, but
- 59:58they also have a very
- 59:59low penetrance, for example, titin.
- 01:00:01So this is how you
- 01:00:03wanna answer that. Second thing
- 01:00:04I wanna have actually at
- 01:00:06the basic level. You mentioned
- 01:00:07actually amyloid,
- 01:00:09kind of deposition,
- 01:00:10autophagy, and then you came
- 01:00:12AMPK that actually if it's
- 01:00:13defective causes
- 01:00:14reduced autophagy. I wonder if
- 01:00:16that could be a readout
- 01:00:17for your
- 01:00:18single for for your iPSCs
- 01:00:20because you don't have actually
- 01:00:21great readout. That actually maybe
- 01:00:23autophagy is actually the one
- 01:00:24of the major
- 01:00:25readout for the drug.
- 01:00:27Yeah. Those are great questions
- 01:00:28and suggestions. So I think,
- 01:00:30you know, this idea of
- 01:00:31penetrance is really interesting. To
- 01:00:33be able to take your
- 01:00:35familial,
- 01:00:37you know, your familial disease
- 01:00:39and you know what their
- 01:00:40genotype is, and then you
- 01:00:41have a family that, you
- 01:00:43know, maybe you have penetrance
- 01:00:44or not. And then maybe
- 01:00:46incorporate the GWAS, the the
- 01:00:48polygenic risk scores, the the
- 01:00:51common variants and how they
- 01:00:52influence penetrance would be really
- 01:00:54interesting.
- 01:00:55I don't know that we
- 01:00:56have done that in AF
- 01:00:58as of yet, but that's
- 01:00:59would be one approach, I
- 01:01:00think.
- 01:01:01And then
- 01:01:02you're right. For the for
- 01:01:05we don't have a good
- 01:01:06phenotype
- 01:01:07in an iPS cell cardiomyocyte.
- 01:01:09They just, you know, they
- 01:01:10don't
- 01:01:11they don't even have a
- 01:01:12lot of
- 01:01:14a lot of irregularity. I
- 01:01:15think we can look at
- 01:01:16calcium,
- 01:01:17studies. It's not high throughput.
- 01:01:19But if we can find
- 01:01:20a,
- 01:01:22you know, like a signature
- 01:01:23of AF that we can
- 01:01:24then assay for biochemically
- 01:01:26or with, you know, RTPC
- 01:01:28or something, that would be
- 01:01:29that's what we're working on
- 01:01:30next because
- 01:01:31and I and I have
- 01:01:32to say over the last
- 01:01:33year, I probably should have
- 01:01:34come on that a lot
- 01:01:35earlier and worked on that,
- 01:01:37earlier in this grant to
- 01:01:38try to figure out we
- 01:01:40were we that we were
- 01:01:41we've been working so hard
- 01:01:42on trying to figure out
- 01:01:43the right triggers and stress
- 01:01:45to do, but still, you
- 01:01:46know, the phenotype is really
- 01:01:48difficult if you're relying on,
- 01:01:50RNA seek to what we
- 01:01:52were what we had proposed
- 01:01:53that we were gonna use
- 01:01:54an RNA seek profile where
- 01:01:56we have our left atrial
- 01:01:57appendages in AF versus non
- 01:02:00AF in sinus rhythm. So
- 01:02:01you have a transcriptomic
- 01:02:03profile there. And the goal
- 01:02:04is with pacing stress. I
- 01:02:06didn't show you some of
- 01:02:07the stuff we have done
- 01:02:08with pacing stress and, and
- 01:02:10testing the drugs.
- 01:02:12We are doing pacing stress,
- 01:02:14and we look at the
- 01:02:15the gene's expression
- 01:02:17that is going in a
- 01:02:18similar direction as AFib might
- 01:02:20in the left atrial appendage
- 01:02:21in the human, and then,
- 01:02:23looking for drugs that then
- 01:02:25reduce it back to a
- 01:02:26more sinus rhythm profile.
- 01:02:28So using that as a
- 01:02:29potential score is some way
- 01:02:32to to try to narrow
- 01:02:33the list. Otherwise, you're with,
- 01:02:34like, that heat map. You
- 01:02:36have this
- 01:02:37dizzying
- 01:02:38list of drugs, and how
- 01:02:39are you going to,
- 01:02:41how are you going to
- 01:02:42curate them other than just
- 01:02:43manually? So but you're you're
- 01:02:45right. Maybe looking at some
- 01:02:47mitophagy
- 01:02:48type,
- 01:02:49marker might be actually
- 01:02:51helpful too. Yeah. Thanks. Glad
- 01:02:53to be, thanks, doctor Tom,
- 01:02:55for coming in.
- 01:02:57Thank you. Thank you so
- 01:02:59much.